Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243908 | 0.87 | HRH3 (0.58) | HRH3MTNR1AMTNR1BCHRNA7HSD11B1 | |
| SCHEMBL3243916 | 0.87 | HRH3 (0.54) | HRH3KMT2AALDH1A1MTNR1AMTNR1B | |
| SCHEMBL3242788 | 0.86 | HRH3 (0.53) | HRH3MTNR1AMTNR1BCHRNA7HSD11B1 | |
| SCHEMBL3238692 | 0.86 | HRH3 (0.53) | HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL3238711 | 0.86 | HRH3 (0.53) | HRH3KMT2AMEN1MTNR1AMTNR1B | |
| SCHEMBL3243212 | 0.84 | HRH3 (0.51) | HRH3MTNR1AMTNR1BCHRNA7 | |
| SCHEMBL3249148 | 0.84 | HRH3 (0.51) | HRH3ALDH1A1MTNR1AMTNR1BHSD11B1 | |
| SCHEMBL3242779 | 0.84 | HRH3 (0.55) | HRH3MTNR1AMTNR1B | |
| SCHEMBL3242758 | 0.84 | HRH3 (0.55) | HRH3MTNR1AMTNR1B | |
| SCHEMBL3238698 | 0.83 | HRH3 (0.61) | HRH3MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426428-B2 | EGFR kinase knockdown via electrophilically enhanced inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100144705-A1 | EGFR KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2069331-B1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| EP-2069331-A1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-7514433-B2 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080032976-A1 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-07 | — | — | US | disclosed |
| WO-2008015125-A1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144705-A1 | EGFR KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | EGFR, ERBB2, ERBB3 | HRH3 3087/4885KMT2A 1179/4885MEN1 3422/4885 |
| US-20080032976-A1 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | HTR6, HTR1A, HRH4 | HRH3 5/4885KMT2A 779/4885MEN1 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.